Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ProPhase Labs Inc
PRPH | US
0.14
USD-0.01
-6.29%
PRPH | US
About ProPhase Labs Inc
Sector
Healthcare
Industry
Drug Manufacturers - Major
Earnings date
30/06/2024
As of date
12/03/2026
Close
0.14
Open
0.15
High
0.15
Low
0.14
ProPhase Labs Inc. engages in the development and commercialization of novel drugs dietary supplements and compounds in the United States. The company operates in two segments Diagnostic Services and Consumer Products. It provides a range of OTC dietary supplements including Legendz XL for male sexual health; and Triple Edge XL an energy and stamina booster. The company also offers contract manufacturing services such as consumer product development pre-commercialization production warehousing and distribution; COVID-19 diagnostic information services to a range of customers including health plans third party payers and government organizations; and respiratory pathogen panel molecular testing services as well as personal genomics products and services. In addition it is involved in the research development manufacture distribution marketing and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs Inc. was founded in 1989 and is headquartered in Garden City New York.
View LessPRPH | US
Risk
74.5
Sharpe
-0.66
Luna's Score
33/100
Recommendation
Sell
Luna says (PRPH | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Value Stock (Price to Book < 3)
What's not Working
Weakness based on declining price with high volume
Price Below SMA10D
High 6-Month Volatility (>65%)
High Current Volume and Negative 1-Day Return
Microcap (<300M USD)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
81.0%1 month
74.5%3 months
189.6%6 months
160.6%Returns
Fundamental Ratios
PE
-
Fwd. PE
10.09
Price to book
1.04
Debt to equity
0.61
Debt to assets
0.29
Ent. to EBITDA
2.45
Ent. to rev.
3.94
PEG
-
Other Fundamentals
EBITDA
-27.01M
MarketCap
2.67M
MarketCap(USD)
2.67M
Div. yield
-
Op. margin
-316.37
Erngs. growth
-95.20
Rev. growth
-81.30
Ret. on equity
-50.92
Short ratio
6.60
Short perc.
1.45
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.05
Range1M
0.07
Range3M
1.07
Volumes: Market Activity
Rel. volume
2.01
Price X volume
38.72K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 2.45 | - | Cheaper |
| Ent. to Revenue | 3.94 | - | Cheaper |
| PE Ratio | - | 41.17 | - |
| Price to Book | 1.04 | 11.46 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 189.63 | - | Riskier |
| Debt to Equity | 0.61 | 1.72 | Cheaper |
| Debt to Assets | 0.29 | 0.31 | Par |
| Market Cap | 2.67M | - | Emerging |
